# Fred Shane

> Fred Shane is a Series B investor at Axil Capital (Tokyo) backing Biotechnology and Health Care. See 4 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Axil Capital](https://shizune.co/investors/profile/axil-capital)
- Location: Tokyo, Japan
- Total investments: 4
- Last investment: Mar 2021
- Lead investor: 75%
- Last updated: Aug 2026

Fred Shane is a Managing Partner of Axil Capital. Fred heads the global investment team, and he is the portfolio manager for Axil’s global investments. Fred has played an integral role in co-founding and expanding Axil Capital from its inception in 2017. Fred is a seasoned investment professional with extensive experience in the VC, PE, andinvestment banking industries, where he has assumed a number of key positions at multiple prominent organizations. Prior to co-founding Axil, Fred was a Director in the Investment Business Department of Mizuho Securities. Prior to Mizuho, Fred was instrumental in setting up the biotech investment operations at Marubeni USA, where he gained deep experience in evaluating, executing and building value in biotech startups through the full lifecycle of the deal. Fred received his B.S. degree in Electrical Engineering & Computer Science from M.I.T.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 3 | 75% |
| Health Care | 2 | 50% |
| Medical | 1 | 25% |
| Genetics | 1 | 25% |
| Pharmaceutical | 1 | 25% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 2 | 50% |
| Series A | 1 | 25% |
| Funding Round | 1 | 25% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Japan | 1 | 25% |
| Israel | 1 | 25% |
| United States | 1 | 25% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| TechsoMed | TechsoMed is an Israeli based medical device company, developing ultrasound based real-time monitoring systems for thermal ablation procedures. The applications of thermal ablation are numerous: tumor destruction, heart arrhythmia, blood pressure treatments and more. The procedure has market size in the billions, but lacks real-time monitoringcapabilities, causing high failure rates.Their technology offers added value to patients, physicians and insurance companies by solving the high failure rate of these minimally invasive and cost effective procedures. | $7M | Series B | Mar 03, 2021 |  |
| LUCA Science | LUCA Science develops innovative treatments intended for mitochondrial and related diseases. | $9.8M | Series A | Sep 01, 2020 |  |
| TechsoMed | TechsoMed is an Israeli based medical device company, developing ultrasound based real-time monitoring systems for thermal ablation procedures. The applications of thermal ablation are numerous: tumor destruction, heart arrhythmia, blood pressure treatments and more. The procedure has market size in the billions, but lacks real-time monitoringcapabilities, causing high failure rates.Their technology offers added value to patients, physicians and insurance companies by solving the high failure rate of these minimally invasive and cost effective procedures. | $2.6M |  | May 30, 2019 |  |
| Frequency Therapeutics | Frequency Therapeutics develops small molecule drugs that activate progenitor cells within the body to restore healthy tissue. Through the transitory activation of these progenitor cells, Frequency enables disease modification without the complexity of genetic engineering. It was founded in 2015 and headquartered in Woburn, Massachusetts. | $42M | Series B | Jan 07, 2019 |  |

4 of 4 investments shown.

## Co-investors
- [Cobro Ventures](https://shizune.co/investors/profile/cobro-ventures) — VC Fund, 2 deals together
- [Johnson & Johnson Innovation](https://shizune.co/investors/profile/johnson-johnson-innovation-jjdc) — VC Fund, 2 deals together
- [NextLeap Ventures](https://shizune.co/investors/profile/nextleap-ventures) — VC Fund, 2 deals together
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund, 1 deal together
- [Cahc co., Ltd.](https://shizune.co/investors/profile/cahc-co-ltd) — VC Fund, 1 deal together
- [Emigrant Capital](https://shizune.co/investors/profile/emigrant-capital) — VC Fund, 1 deal together

## About Axil Capital

VC Fund · Tokyo, Japan

Axil Capital is a venture capital firm investing in companies in the biomedical and healthcare fields from the early stages.

2 contacts available at Axil Capital.

| Name | Title | Profile |
| --- | --- | --- |
| Fred Shane | Managing Partner & Co-Founder | https://shizune.co/investors/profile/fred-shane |
| Hiroshi Gonaikawa | Co-Founder & Partner | https://shizune.co/investors/profile/hiroshi-gonaikawa |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Fred Shane invest in?

Fred Shane invests primarily in Biotechnology, Health Care and Medical startups, most often at Series B and Series A stage. Most of the 4 investments tracked by Shizune back companies in Japan. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Fred Shane last invest?

The most recent investment recorded for Fred Shane closed in Mar 2021. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co